亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

无容量 医学 肝细胞癌 索拉非尼 内科学 丙型肝炎病毒 丙型肝炎 肿瘤科 乙型肝炎 胃肠病学 免疫疗法 免疫学 癌症 病毒
作者
Anthony B. El-Khoueiry,Bruno Sangro,Thomas Yau,Todd S. Crocenzi,Masatoshi Kudo,Chiun Hsu,Tae‐You Kim,Su-Pin Choo,Jörg Trojan,Theodore H. Welling,Tim Meyer,Yoon‐Koo Kang,Winnie Yeo,Akhil Chopra,Jeffrey Anderson,Christine Dela Cruz,Lixin Lang,Jaclyn Neely,Hao Tang,Homa Dastani,Ignacio Melero
出处
期刊:The Lancet [Elsevier]
卷期号:389 (10088): 2492-2502 被引量:3658
标识
DOI:10.1016/s0140-6736(17)31046-2
摘要

Summary

Background

For patients with advanced hepatocellular carcinoma, sorafenib is the only approved drug worldwide, and outcomes remain poor. We aimed to assess the safety and efficacy of nivolumab, a programmed cell death protein-1 (PD-1) immune checkpoint inhibitor, in patients with advanced hepatocellular carcinoma with or without chronic viral hepatitis.

Methods

We did a phase 1/2, open-label, non-comparative, dose escalation and expansion trial (CheckMate 040) of nivolumab in adults (≥18 years) with histologically confirmed advanced hepatocellular carcinoma with or without hepatitis C or B (HCV or HBV) infection. Previous sorafenib treatment was allowed. A dose-escalation phase was conducted at seven hospitals or academic centres in four countries or territories (USA, Spain, Hong Kong, and Singapore) and a dose-expansion phase was conducted at an additional 39 sites in 11 countries (Canada, UK, Germany, Italy, Japan, South Korea, Taiwan). At screening, eligible patients had Child-Pugh scores of 7 or less (Child-Pugh A or B7) for the dose-escalation phase and 6 or less (Child-Pugh A) for the dose-expansion phase, and an Eastern Cooperative Oncology Group performance status of 1 or less. Patients with HBV infection had to be receiving effective antiviral therapy (viral load <100 IU/mL); antiviral therapy was not required for patients with HCV infection. We excluded patients previously treated with an agent targeting T-cell costimulation or checkpoint pathways. Patients received intravenous nivolumab 0·1–10 mg/kg every 2 weeks in the dose-escalation phase (3+3 design). Nivolumab 3 mg/kg was given every 2 weeks in the dose-expansion phase to patients in four cohorts: sorafenib untreated or intolerant without viral hepatitis, sorafenib progressor without viral hepatitis, HCV infected, and HBV infected. Primary endpoints were safety and tolerability for the escalation phase and objective response rate (Response Evaluation Criteria In Solid Tumors version 1.1) for the expansion phase. This study is registered with ClinicalTrials.gov, number NCT01658878.

Findings

Between Nov 26, 2012, and Aug 8, 2016, 262 eligible patients were treated (48 patients in the dose-escalation phase and 214 in the dose-expansion phase). 202 (77%) of 262 patients have completed treatment and follow-up is ongoing. During dose escalation, nivolumab showed a manageable safety profile, including acceptable tolerability. In this phase, 46 (96%) of 48 patients discontinued treatment, 42 (88%) due to disease progression. Incidence of treatment-related adverse events did not seem to be associated with dose and no maximum tolerated dose was reached. 12 (25%) of 48 patients had grade 3/4 treatment-related adverse events. Three (6%) patients had treatment-related serious adverse events (pemphigoid, adrenal insufficiency, liver disorder). 30 (63%) of 48 patients in the dose-escalation phase died (not determined to be related to nivolumab therapy). Nivolumab 3 mg/kg was chosen for dose expansion. The objective response rate was 20% (95% CI 15–26) in patients treated with nivolumab 3 mg/kg in the dose-expansion phase and 15% (95% CI 6–28) in the dose-escalation phase.

Interpretation

Nivolumab had a manageable safety profile and no new signals were observed in patients with advanced hepatocellular carcinoma. Durable objective responses show the potential of nivolumab for treatment of advanced hepatocellular carcinoma.

Funding

Bristol-Myers Squibb.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
LUMO完成签到 ,获得积分10
8秒前
Tei完成签到,获得积分10
24秒前
26秒前
英俊的铭应助阿a采纳,获得10
1分钟前
1分钟前
阿a发布了新的文献求助10
1分钟前
moom完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
2分钟前
赘婿应助科研通管家采纳,获得30
2分钟前
马梦秋发布了新的文献求助10
2分钟前
3分钟前
3分钟前
3分钟前
充电宝应助欢呼的寻双采纳,获得10
3分钟前
CodeCraft应助泓凯骏采纳,获得10
3分钟前
3分钟前
泓凯骏发布了新的文献求助10
3分钟前
淡定落雁发布了新的文献求助30
3分钟前
淡定落雁完成签到,获得积分10
3分钟前
ninomae完成签到 ,获得积分10
4分钟前
4分钟前
哲别发布了新的文献求助10
4分钟前
5分钟前
5分钟前
哲别发布了新的文献求助10
5分钟前
小二郎应助哲别采纳,获得10
5分钟前
Wish完成签到,获得积分10
5分钟前
菜菜完成签到,获得积分10
7分钟前
7分钟前
菜菜发布了新的文献求助10
7分钟前
Jayden完成签到 ,获得积分10
8分钟前
10分钟前
思源应助科研通管家采纳,获得10
10分钟前
iamzhangly30hyit完成签到 ,获得积分10
10分钟前
lalala大鸭梨完成签到,获得积分10
11分钟前
阿杰完成签到 ,获得积分10
11分钟前
科研通AI2S应助科研通管家采纳,获得10
12分钟前
隐形曼青应助健忘绿茶采纳,获得10
12分钟前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Le dégorgement réflexe des Acridiens 800
Defense against predation 800
Very-high-order BVD Schemes Using β-variable THINC Method 568
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3137011
求助须知:如何正确求助?哪些是违规求助? 2787960
关于积分的说明 7784146
捐赠科研通 2444060
什么是DOI,文献DOI怎么找? 1299705
科研通“疑难数据库(出版商)”最低求助积分说明 625497
版权声明 600997